Trump signs order to accelerate access to psychedelic drug treatments

Trump signs order to accelerate access to psychedelic drug treatments

The order will pave the way for drugs which can cause hallucinations and are largely illegal to be reclassified after successful clinical trials.

Donald Trump
The order signed by President Donald Trump directs the US Food and Drug Administration to fast-track review of drugs such as ibogaine, which is said could help treat post-traumatic stress disorder.   (EPA Images pic)
WASHINGTON:
US President Donald Trump on Saturday signed an executive order intended to speed up access to medical research and treatment based on psychedelic drugs.

The order instructs the US Food and Drug Administration to expedite review of drugs such as ibogaine, a drug that US military veteran groups have said can help treat post-traumatic stress disorder.

At an event in the Oval Office, US federal officials said that the reforms would pave the way for the drugs, which can cause hallucinations and are largely illegal, to be reclassified after successful clinical trials. Trump also said the US would dedicate US$50 million to federal research into ibogaine.

Health Secretary ​Robert F. Kennedy Jr. has championed the idea of using drugs such as ibogaine as an alternative treatment for mental health conditions such as depression.

US Food and Drug Administration Commissioner Marty Makary on Saturday said that decisions on the drugs could come as soon as this summer.

Stay current - Follow FMT on WhatsApp, Google news and Telegram

Subscribe to our newsletter and get news delivered to your mailbox.